Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 5.5% – Tale of the Tape

The stock has witnessed four downward estimate revisions in the past 30 days. The Zacks Consensus Estimate has also moved down over same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher lasts.

Supernus Pharmaceuticals carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

A stock worth considering in the drugs – generic industry is Akorn, Inc. (AKRX), sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>